| Literature DB >> 29142518 |
Myeongsook Seo1, Eun Mi Song1, Gwang Un Kim1, Sung Wook Hwang1, Sang Hyoung Park1, Dong-Hoon Yang1, Kyung-Jo Kim1, Byong Duk Ye1, Seung-Jae Myung1, Suk-Kyun Yang1, Jeong-Sik Byeon1.
Abstract
BACKGROUND/AIMS: Precutting before endoscopic piecemeal mucosal resection (EPMR) may increase colorectal polyp resection effectiveness. We aimed to identify risk factors for recurrence after conventional EPMR (CEPMR) and precut EPMR (PEPMR) and investigated endoscopic treatment outcomes for recurrent cases.Entities:
Keywords: Colonic neoplasia; Endoscopic mucosal resection; Piecemeal resection
Year: 2017 PMID: 29142518 PMCID: PMC5683981 DOI: 10.5217/ir.2017.15.4.502
Source DB: PubMed Journal: Intest Res ISSN: 1598-9100
Fig. 1Flow diagram showing recurrence and subsequent endoscopic treatment. aEarly recurrence (red box) rates at the first surveillance were 5.8% (18/312) and 6.4% (3/47) after conventional endoscopic piecemeal mucosal resection (CEPMR) and precut EPMR (PEPMR), respectively; bAmong lesions without recurrence at the first surveillance colonoscopy, the rates of late recurrence (blue box) were 3.9% (6/152) and 0% after CEPMR and PEPMR, respectively. In summary, the overall recurrence rates were 7.7% (24/312) and 6.4% (3/47) after CEPMR and PEPMR, respectively.
Fig. 2Conventional endoscopic piecemeal resection (EPMR) (A-E) and precut EPMR (F-J).
Baseline Characteristics of Patients, Polyps, and EPMR Procedures
| CEPMR (n=312) | PEPMR (n=47) | ||
|---|---|---|---|
| Age (yr) | 63.0±9.8 | 62.3±9.9 | 0.629 |
| Male sex | 196 (62.8) | 29 (61.7) | 0.883 |
| Experienced endoscopists | 296 (94.9) | 45 (95.7) | >0.999 |
| Location of lesions | <0.001 | ||
| Cecum-ascending colon | 175 (55.8) | 11 (23.4) | |
| Transverse colon | 52 (16.7) | 10 (21.3) | |
| Descending colon-sigmoid colon | 53 (17.0) | 12 (25.5) | |
| Rectum | 33 (10.6) | 14 (29.8) | |
| Morphology of lesions | 0.642 | ||
| LST-G | 127 (40.7) | 21 (44.7) | |
| LST-NG | 135 (43.3) | 17 (36.2) | |
| Sessile/protruded | 50 (16.0) | 9 (19.1) | |
| Prior biopsy | 0.075 | ||
| No | 75 (24.0) | 6 (12.8) | |
| Yes | 231 (74.0) | 38 (80.9) | |
| Unknown | 5 (1.6) | 3 (6.4) | |
| Lesion size (mm) | 23.7±12.0 | 28.5±15.4 | 0.009 |
| Non-lifting sign | 50 (16.0) | 10 (21.7) | 0.333 |
| Supplementary procedures after EPMR | 0.310 | ||
| None | 94 (30.1) | 21 (44.7) | |
| Avulsion by hot biopsy forceps | 26 (8.3) | 4 (8.5) | |
| APC | 153 (49.0) | 19 (40.4) | |
| Avulsion+APC | 3 (1.0) | 0 | |
| Snare tip coagulation | 36 (11.5) | 3 (6.4) |
Values are presented as mean±SD or number (%)
EPMR, endoscopic piecemeal mucosal resection; CEPMR, conventional EPMR; PEPMR, precut EPMR; LST-G, laterally spreading tumor-granular type; LST-NG, LST-nongranular type; APC, argon plasma coagulation.
Clinical Outcomes after EPMR
| CEPMR (n=312) | PEPMR (n=47) | ||
|---|---|---|---|
| No. of resected pieces | 3.4±2.3 | 3.2±1.7 | 0.903 |
| Histology | 0.072 | ||
| Adenoma/low grade dysplasia | 173 (55.4) | 23 (48.9) | |
| Adenoma/high grade dysplasia | 63 (20.2) | 14 (29.8) | |
| Sessile serrated adenoma/polyp | 28 (9.0) | 0 | |
| Mucosal cancer | 33 (10.6) | 7 (14.9) | |
| Superficial submucosal cancer | 6 (1.9) | 3 (6.4) | |
| Deep submucosal cancera | 1 (0.3) | 0 | |
| Others | 8 (2.6) | 0 | |
| Histological complete resection | 125 (40.1) | 15 (31.9) | 0.003 |
| Complication | |||
| Perforation | 3 (1.0) | 1 (2.1) | 0.431 |
| Intraprocedural bleeding | 39 (12.5) | 15 (31.9) | 0.001 |
| Delayed bleeding | |||
| Early delayed bleeding (≤48 hr) | 9 (2.9) | 3 (6.4) | 0.198 |
| Late delayed bleeding (>48 hr) | 3 (1.0) | 1 (2.1) | 0.431 |
| Follow-up duration (mo) | 20.5 (12.3–38.2) | 18.2 (12.1–43.0) | 0.696 |
| No. of surveillance endoscopies | 2.0±1.2 | 2.1±1.1 | 0.258 |
| Overall recurrence | 24 (7.7) | 3 (6.4) | 0.751 |
Values are presented as mean±SD, number (%), or median (interquartile range).
aThe patient refused additional surgery because of existing comorbidities of liver cirrhosis and lymphoma. She was followed up for 12 months without recurrence, but died of septic shock as a complication of lymphoma treatment after 3 years.
EPMR, endoscopic piecemeal mucosal resection; CEPMR, conventional EPMR; PEPMR, precut EPMR.
Recurrence Rates According to Lesion Size
| Recurrence rate | CEPMR (n=312) | PEPMR (n=47) | Total (n=359) | |
|---|---|---|---|---|
| Overall recurrence | 7.7 (24/312) | 6.4 (3/47) | 7.5 (27/359) | >0.999 |
| Recurrence in polyps ≥20 mm | 10.6 (21/199) | 7.9 (3/38) | 10.1 (24/237) | 0.775 |
| Recurrence according to tumor size (mm) | ||||
| 10–19 | 2.7 (3/113) | 0 (0/9) | 2.5 (3/122) | >0.999 |
| 20–29 | 7.4 (8/108) | 12.5 (2/16) | 8.1 (10/124) | 0.626 |
| 30–39 | 12.1 (7/58) | 0 (0/13) | 9.9 (7/71) | 0.601 |
| ≥40 | 18.2 (6/33) | 11.1 (1/9) | 16.7 (7/42) | >0.999 |
| 0.001 | 0.727 | 0.002 |
Values are presented as percent (number/total number).
CEPMR, conventional endoscopic piecemeal mucosal resection; PEPMR, precut EPMR.
Univariate and Multivariate Analyses of Risk Factors for Local Recurrence
| Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
| OR (95% CI) | OR (95% CI) | |||
| Size of lesion (mm) | 0.016 | 0.015 | ||
| <20 | 1 (reference) | 1 (reference) | ||
| 20–39 | 3.79 (1.09–13.21) | 3.79 (1.09–13.21) | 0.037 | |
| ≥40 | 7.93 (1.95–32.30) | 7.93 (1.95–32.30) | <0.001 | |
| Morphology of lesion | 0.005 | |||
| Sessile/protruded | 1 (reference) | |||
| LST-NG | 1.58 (0.36–6.81) | |||
| LST-G | 4.33 (1.57–11.93) | |||
| No. of pieces | 0.019 | |||
| <4 | 1 (reference) | |||
| ≥4 | 2.58 (1.17–5.69) | |||
| Perforation | 0.032 | |||
| No | 1 (reference) | |||
| Yes | 4.47 (1.14–17.67) | |||
LST-NG, laterally spreading tumor-nongranular type; LST-G, LST-granular type.
Endoscopic Treatment Methods for the First Recurrent Lesionsa after EPMR
| Treatment modalities | No. of cases (%) |
|---|---|
| Single modality | 8 (29.6) |
| Cold forceps polypectomy | 5 (18.5) |
| EMR | 3 (11.1) |
| Combination modality | 19 (70.4) |
| Cold forceps polypectomy+APC | 6 (22.2) |
| Hot biopsy+APC | 2 (7.4) |
| EMR+APC | 7 (25.9) |
| EMR+hot biopsy | 3 (11.1) |
| EMR+hot biopsy+APC | 1 (3.7) |
aThe first recurrent lesions included both initial recurrences at the first surveillance endoscopy (n=21) and late recurrences at the second and third surveillance endoscopies without recurrence at the first surveillance endoscopy (n=6).
EPMR, endoscopic piecemeal mucosal resection; EMR, endoscopic mucosal resection; APC, argon plasma coagulation.